Gland Pharma IPO-Date, Review and Details

Gland Pharma has robust business model and strong financial performance since 2017 when Fosun took over major stake; post IPO its stake would come down to 58%. The IPO is worth investing if the geopolitical tension remains subdued. However investors wary of external risk may consider investing based on their risk appetite.

Bodhi Tree IPO Synopsis

Bodhi Tree Multimedia Ltd. IPO Synopsis

Bodhi Tree has diversified production portfolio and is widespread geographically but its strengths are offset by negative net worth and high volatility in its financial performance which puts a question mark over its sustainability of revenues. The NAV of the issuer is negative at 23.43 and IPO is valued at Rs 95 which hints at overvaluation. Thus, Investors should stay away from this IPO.